EyePoint, Inc.

Contributing Author

Recent Articles by EyePoint, Inc.

Mar-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Mar-04	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Mar-02	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema EYPT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information